# Workshop on Characterization of Nanomaterials for Medical and Health Applications

**Jointly sponsored by**

**ASTM, NCI, NIST and U.S. FDA**

May 19, 2005 - Reno, NV

http://www.astm.org/MEETINGS/COMMIT/E56wkshp.html

# Workshop Questions

1. Based on the history of the in-vitro characterization of materials for drug applications, what characteristics are important for consideration of nanomaterials in this application? Are there any characteristics not previously important that are new for nanomaterials?

2. Given the literature available on characterization of nanomaterials for use as pharmaceuticals, what are the characteristics for which we should we try to develop standard test methods for the in-vitro characterization of nanomaterials for drug applications?

# Workshop Questions

3. What infrastructure support does the nanotech researcher need to better characterize their nanomaterial against these standard methods? (e.g., access to instrumentation, batch-to-batch analysis, experimental design, assay development/validation).

4. With respect to the above questions, how do we design the validation experiment for the methods we determine are important? What 3rd party entity will be acceptable/"recognized" to evaluate the validation experiment? Can we do the validation as an "ASTM E56 standards community"?